Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials

Annals of Oncology

Volumn 21, Issue 9, 2010, Pages 1743-1750

  Bujko, K ^a   Glynne Jones, R ^b   Bujko, M ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

Adjuvant chemotherapy; Neoadjuvant radiation; Rectal cancer

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; HUMAN; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; RECTUM RESECTION; REVIEW; SYSTEMATIC REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FLUOROURACIL; HUMANS; LEUCOVORIN; NEOADJUVANT THERAPY; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECTAL NEOPLASMS;

EID: 77954399498     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq054     Document Type: Review

References (55)

1. Frykholm GJ, Glimelius B, Pahlman L. Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and evaluation of late secondary effects. Dis Colon Rectum 1993; 36: 564-572.
2. Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-1740.
3. Sakamoto J, Hamada C, Kodaira S et al. Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: individual patient data meta-analysis of randomized trials. Jap J Clin Oncol 1999; 29: 78-86.
4. Sakamoto J, Hamada C, Yoshida S et al. An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer. Br J Cancer 2007; 96: 1170-1177.
5. Kusters M, Beets GL, van de Velde CJ et al. A comparison between the treatment of low rectal cancer in Japan and the Netherlands, focusing on the patterns of local recurrence. Ann Surg 2009; 249: 229-235.
6. QUASAR Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370: 2020-2029.
7. Rectal cancer V.2. NCCN Clinical Practical Guidelines in Oncology 2010; http://www.nccn.org/professionals/physician_gls/PDF/rectal.pdf (24 February 2010, date last accessed).
8. Glimelius B, Oliveira J. ESMO Guidelines Working Group. Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl 4): 54-56.
9. Valentini V, Aristei C. Glimelius B et al. Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECACC2). Radiother Oncol 2009; 92: 148-163.
10. Bosset JF, Collette L, Calais G et al. Chemoradiotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114-1123.
11. Collette L, Bosset JF, den Dulk M et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 2007; 25: 4379-4386.
12. Wan DS. Reevaluation of intraluminal fluorouracil chemotherapy as an adjuvant to radical resection of colorectal cancer-results of a randomized trial. Zhonghua Zhong Liu Za Zhi 1988; 10: 388-391.
13. Li RL. Combination of surgery, radiotherapy and chemotherapy for rectal cancer-a 423 cases report. Zhonghua Zhong Liu Za Zhi 1992; 14: 213-215.
14. Hojo K, Kajitani T. Adjuvant chemotherapy of colorectal cancer-results of prospective randomized trials. Gan To Kagaku Ryoho 1986; 13: 3063-3073.
15. Meta-Analysis Group of the Japanese Society for Cancer of the Colon and Rectum and the Meta-Analysis Group in Cancer. Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol 2004; 22: 484-492.
16. Fisher B, Wolmark N, Rockette H et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst 1988; 2: 21-29.
17. Swiss Group for Clinical Cancer Research (SAKK). Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Lancet 1995; 11: 349-353.
18. Dahl O, Fluge Ø, Carlsen E et al. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. Acta Oncol 2009; 48: 368-376.
19. Lawrence W Jr, Terz JJ, Horsley S et al. Chemotherapy as an adjuvant to surgery for colorectal cancer. Ann Surg 1975; 181: 616-623.
20. Abdi EA, Hanson J, Harbora DE et al. Adjuvant chemoimmuno-and immunotherapy in Dukes' stage B2 and C colorectal carcinoma: a 7-year followup analysis. J Surg Oncol 1989; 40: 205-213.
21. Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med 1985; 312: 1465-1472.
22. Hafström L, Domellöf L, Rudenstam CM et al. Adjuvant chemotherapy with 5-fluorouracil, vincristine and CCNU for patients with Dukes' C colorectal cancer. Br J Surg 1990; 77: 1345-1348.
23. Hafström L, Rudenstam CM, Domellöf L. A randomized trial of oral 5-fluorouracil versus placebo as adjuvant therapy in colorectal cancer Dukes' B and C: results after 5 years observation time. Br J Surg 1985; 72: 138-141.
24. Fielding LP, Hittinger R, Grace RH, Fry JS. Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma. Lancet 1992; 29: 502-506.
25. Grossi CE, Wolff WI, Nealon TF et al. Intraluminal fluorouracil chemotherapy adjunct to surgical procedures for resectable carcinoma of the colon and rectum. Surg Gynecol Obstet 1977; 145: 549-554.
26. Higgins GA Jr, Amadeo JH, McElhinney J et al. Efficacy of prolonged intermittent therapy with combined 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel. A Veterans Administration Surgical Oncology Group report. Cancer 1984; 1: 1-8.
27. Grage TB, Moss SE. Adjuvant chemotherapy in cancer of the colon and rectum: demonstration of effectiveness of prolonged 5-FU chemotherapy in a prospectively controlled, randomized trial. Surg Clin North Am 1981; 61: 1321-1329.
28. Taylor I, Machin D, Mullee M et al. A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br J Surg 1985; 72: 359-363.
29. Glimelius B, Dahl O, Cedermark B et al. Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncol 2005; 44: 904-912.
30. Rougier P, Sahmoud T, Nitti D et al. Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. Lancet 1998; 351: 1677-1681.
31. The AXIS collaborators. Randomized clinical trial of adjuvant radiotherapy and 5-fluorouracil infusion in colorectal cancer (AXIS). Br J Surg 2003; 90: 1200-1212.
32. Fountzilas G, Zisiadis A, Dafni U et al. Postoperative radiation and concomitant bolus fluorouracil with or without additional chemotherapy with fluorouracil and high-dose leucovorin in patients with high-risk rectal cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 1999; 10: 671-676.
33. Cafiero F, Gipponi M, Peressini A et al. Preliminary analysis of a randomized clinical trial of adjuvant postoperative RT vs. postoperative RT plus 5-Fu and levamisole in patients with TNM stage II-III resectable rectal cancer. J Surg Oncol 2000; 75: 80-88.
34. Taal BG, Van Tinteren H, Zoetmulder FA. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer 2001; 85: 1437-443.
35. Mansour EG, Lefkopoulou M, Johnson R, Douglass HO. A comparison of postoperative adjuvant chemotherapy, radiotherapy or combination therapy in potentially curable resectable rectal carcinoma. An ECOG study EST 4276. Proc Am Soc Clin Oncol 1991; 10: 484 (Abstr).
36. Cionini L, Manfredi B, Sainato A et al. Randomized study of postoperative chemotherapy (CT) after preoperative chemoradiation (CTRT) in locally advanced rectal cancer (LARC). Preliminary results. Eur J Cancer 2001; 37: S300 (Abstr).
37. Gray R, McConkey C. Adjuvant chemotherapy for rectal cancer: authors' reply. Lancet 2008; 371: 1503.
38. Birkenkamp-Demtroder K, Olesen SH, Sorensen FB et al. Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut 2005; 54: 374-384.
39. Fransen K, Klintenas M, Osterstrom A et al. Mutation analysis of the BRAF, ARAF, and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 2004; 25: 527-533.
40. Jonsson M, Ekstrand A, Edekling T et al. Experiences from treatment-predictive KRAS testing; highmutation frequency in rectal cancers from females and concurrent mutations in the same tumour. BMC Clin Pathol 2009; 9: 1-5.
41. Kalady MF, Sanchez JA, Manilich E et al. Divergent oncogenic changes influence survival differences between colon and rectal adenocarcinomas. Dis Colon Rectum 2009; 52: 1039-1045.
42. Krook JE, Moertel CG, Gunderson LL et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991; 324: 709-715.
43. André T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-3116.
44. Collette L, Bosset JF. Adjuvant chemotherapy following neoadjuvant therapy of rectal cancer. The type of neoadjuvant therapy (chemoradiotherpy or radiotherapy) may be important for selection of patients. In reply. J Clin Oncol 2007; 26: 508-509.
45. Sargent D. Time-dependent patterns of failure and treatment benefit from adjuvant therapy for resectable colon cancer: Lessons from the 20,800-patient (pt) ACCENT dataset. J Clin Oncol, ASCO Annual Meeting Proceedings Part I 2007; 25: 18S (June 20 Suppl): 4008 (Abstr).
46. Capirci C, Valentini V, Cionini L et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Rad Oncol Biol Phys 2008; 72: 99-107.
47. Fietkau R, Barten M, Klautke G et al. Postoperative chemotherapy may not be necessary for patients with ypN0-category after neoadjuvant chemoradiotherapy of rectal cancer. Dis Colon Rectum 2006; 49: 1284-1292.
48. Nagtegaal ID, van de Velde CJ, Marijnen CA et al. Low rectal cancer: a call for a change of approach in abdominoperineal resection. J Clin Oncol 2005; 23: 9257-9264.
49. Benzoni E, Terrosu G, Bresadola V et al. Analysis of clinical outcomes and prognostic factors of neoadjuvant chemoradiotherapy combined with surgery: intraperitoneal versus extraperitoneal rectal cancer. Eur J Cancer Care 2006; 15: 286-292.
50. Ludeman L, Shepherd NA. Serosal involvement in gastrointestinal cancer: its assessment and significance. Histopathology 2005; 47: 123-131.
51. Wibe A, Syse A, Andersen E et al. Oncological outcomes after total mesorectal excision for cure for cancer of the lower rectum: anterior vs. abdominoperineal resection. Dis Colon Rectum 2004; 47: 48-58.
52. Pilipshen SJ, Heilweil M, Quan SH et al. Patterns of pelvic recurrence following definitive resections of rectal cancer. Cancer 1984; 53: 1354-1362.
53. Quah HM, Chou JF, Gonen M et al. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer 2008; 113: 57-64.
54. Chan AK, Wong A, Jenken D et al. Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2005; 61: 665-677.
55. Bujko K, Michalski W, Kepka L et al. Association between pathologic response in metastatic lymph nodes after preoperative chemoradiotherapy and risk of distant metastases in rectal cancer: an analysis of outcomes in a randomized trial. Int J Radiat Oncol Biol Phys 2007; 67: 369-377.